Neuraltus Pharmaceuticals Inc. is taking an experimental drug against amyotrophic lateral sclerosis, or Lou Gehrig's disease, into a second mid-stage trial, guided by a previous study that suggested that patients with a specific protein biomarker would respond best.
The 120-patient study by the Palo Alto company is an important one for ALS patients and caregivers who have been frustrated by a handful of failed clinical flameouts of potential ALS drugs. Only one drug, riluzole, is approved for the…
Neuraltus Pharmaceuticals Inc. is taking an experimental drug against amyotrophic lateral sclerosis, or Lou Gehrig's disease, into a second mid-stage trial, guided by a previous study that suggested that patients with a specific protein biomarker would respond best.
The 120-patient study by the Palo Alto company is an important one for ALS patients and caregivers who have been frustrated by a handful of failed clinical flameouts of potential ALS drugs. Only one drug, riluzole, is approved for the…